Equities analysts expect that Inovio Pharmaceuticals Inc (NASDAQ:INO) will post earnings per share of ($0.20) for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Inovio Pharmaceuticals’ earnings, with estimates ranging from ($0.29) to ($0.07). Inovio Pharmaceuticals reported earnings of ($0.08) per share during the same quarter last year, which indicates a negative year over year growth rate of 150%. The business is expected to announce its next quarterly earnings results on Tuesday, August 6th.
On average, analysts expect that Inovio Pharmaceuticals will report full year earnings of ($1.01) per share for the current financial year, with EPS estimates ranging from ($1.06) to ($0.93). For the next year, analysts anticipate that the business will post earnings of ($1.05) per share, with EPS estimates ranging from ($1.22) to ($0.93). Zacks’ EPS calculations are an average based on a survey of research firms that cover Inovio Pharmaceuticals.
Inovio Pharmaceuticals (NASDAQ:INO) last released its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.29) by ($0.01). Inovio Pharmaceuticals had a negative return on equity of 97.95% and a negative net margin of 295.24%. The firm had revenue of $2.83 million for the quarter, compared to analysts’ expectations of $4.44 million.
A number of research firms recently weighed in on INO. HC Wainwright set a $13.00 target price on shares of Inovio Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, April 22nd. Zacks Investment Research lowered shares of Inovio Pharmaceuticals from a “buy” rating to a “hold” rating and set a $3.50 target price on the stock. in a research note on Tuesday, May 28th. BidaskClub lowered shares of Inovio Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, June 1st. Finally, Cantor Fitzgerald began coverage on shares of Inovio Pharmaceuticals in a research note on Monday, March 25th. They set an “overweight” rating and a $3.62 target price on the stock. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. Inovio Pharmaceuticals currently has an average rating of “Buy” and an average price target of $7.22.
Shares of INO stock traded up $0.02 during trading hours on Friday, reaching $2.94. 1,867,806 shares of the stock were exchanged, compared to its average volume of 1,567,792. The stock has a fifty day moving average price of $2.88. The company has a debt-to-equity ratio of 1.02, a current ratio of 4.92 and a quick ratio of 4.92. Inovio Pharmaceuticals has a 12-month low of $2.15 and a 12-month high of $6.30. The stock has a market cap of $288.22 million, a price-to-earnings ratio of -2.80 and a beta of 1.96.
In other Inovio Pharmaceuticals news, insider Laurent Humeau purchased 20,000 shares of the stock in a transaction that occurred on Wednesday, June 5th. The stock was purchased at an average cost of $2.50 per share, with a total value of $50,000.00. Following the completion of the acquisition, the insider now directly owns 45,833 shares of the company’s stock, valued at approximately $114,582.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Jong Joseph Kim sold 136,768 shares of the company’s stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $3.50, for a total value of $478,688.00. Following the completion of the transaction, the chief executive officer now directly owns 2,511,055 shares of the company’s stock, valued at $8,788,692.50. The disclosure for this sale can be found here. Insiders sold 2,866,321 shares of company stock valued at $7,055,433 over the last ninety days. 7.90% of the stock is currently owned by corporate insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. BlackRock Inc. boosted its holdings in Inovio Pharmaceuticals by 4.2% in the fourth quarter. BlackRock Inc. now owns 7,251,925 shares of the biopharmaceutical company’s stock valued at $29,008,000 after purchasing an additional 292,584 shares in the last quarter. Wasatch Advisors Inc. boosted its holdings in shares of Inovio Pharmaceuticals by 9.6% in the first quarter. Wasatch Advisors Inc. now owns 5,848,410 shares of the biopharmaceutical company’s stock valued at $21,815,000 after acquiring an additional 510,480 shares during the period. Nikko Asset Management Americas Inc. acquired a new stake in shares of Inovio Pharmaceuticals in the first quarter valued at approximately $12,169,000. Sumitomo Mitsui Trust Holdings Inc. acquired a new stake in shares of Inovio Pharmaceuticals in the first quarter valued at approximately $11,896,000. Finally, ARK Investment Management LLC boosted its holdings in shares of Inovio Pharmaceuticals by 55.4% in the first quarter. ARK Investment Management LLC now owns 2,929,597 shares of the biopharmaceutical company’s stock valued at $10,927,000 after acquiring an additional 1,043,956 shares during the period. 47.24% of the stock is owned by hedge funds and other institutional investors.
Inovio Pharmaceuticals Company Profile
Inovio Pharmaceuticals, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.
Featured Story: Different Types of Derivatives
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.